- Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.
- Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.
- Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels.
- Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth.
- Benefits infrastructure on track to cover approximately 220 million Americans in second quarter; women’s health offering seeing strong early patient growth.
Conference
call begins at 4:30 p.m. Eastern time today
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the fourth quarter and year ended December 31, 2025.
Management Commentary
“LifeMD delivered strong fourth quarter results across all business lines and is entering its next phase of growth,” said Justin Schreiber, Chairman and CEO of LifeMD. “Our strategy of building a trusted and sustainable platform for virtual healthcare delivery is gaining momentum. Our weight management business is seeing record patient sign-ups in the first quarter at attractive acquisition costs. More than 100 million Americans are clinically eligible for GLP-1 therapy, yet only a fraction are currently being treated—a generational opportunity. Subsequent to year end, we launched oral Wegovy to help patients overcome real barriers around cost, access, and ongoing clinical support. With multiple catalysts ahead—including Medicare coverage for GLP-1 medications, expanded collaborations with GLP-1 manufacturers, and an infrastructure that supports both self-pay and insurance—LifeMD is uniquely positioned for long-term leadership in this transformative market.
“Beyond weight management, our highly differentiated specialty offerings continue to scale. Rex MD, our men’s health brand, delivered strong, profitable growth and recently launched oral Wegovy. Our women’s health business, focused on menopause, hormonal, and bone health, is seeing encouraging early patient growth and represents a deeply underserved population we are uniquely equipped to help. Underpinning all of this is a virtual care infrastructure that we believe sets LifeMD apart and positions the Company for success in the years to come: a 50-state medical benefits infrastructure expected to cover 220 million Americans by end of the second quarter, a highly specialized affiliated provider group, and a national affiliated pharmacy operation. This foundation, combined with unique and growing collaborations with some of the largest healthcare and pharmaceutical brands in the world, uniquely positions LifeMD to capture significant growth in 2026 and the years ahead,” concluded Mr. Schreiber.
“In our first quarter as a pure-play telehealth business, LifeMD delivered solid results with 4% revenue growth and a 348% increase in adjusted EBITDA. Our balance sheet has never been stronger—we exited the year with nearly $37 million in cash and no debt. This financial strength is a key asset as we invest aggressively in the expansion of our rapidly growing and diversifying platform. Our 2026 guidance reflects these investments, with annualized run-rate revenue expected to exceed $250 million and annualized adjusted EBITDA expected to exceed $25 million by the fourth quarter of 2026,” said Marc Benathen, LifeMD’s Chief Financial Officer.
Fourth Quarter Financial Highlights
All comparisons are with the fourth quarter of 2024. Non-GAAP financial measures referenced below are defined and reconciled to GAAP financial measures at the end of this press release.
- Total revenue increased 4% to $46.9 million.
- The number of active telehealth subscribers increased 16% to approximately 323,000 at quarter end.
- Gross margin expanded to 87%, up from 81% in the prior-year period, reflecting favorable revenue mix.
- GAAP net loss from continuing operations attributable to LifeMD, Inc. common stockholders was $1.9 million or $0.04 per share compared to a net loss from continuing operations attributable to LifeMD, Inc. common stockholders of $6.8 million or ($0.16) per share in the prior-year period.
- Including income from discontinued operations related to the sale of WorkSimpli, net income totaled $19.2 million, or $0.41 per share.
- Adjusted EBITDA was $4.8 million compared to $1.1 million in the prior-year period.
- Cash totaled $36.8 million as of December 31, 2025 and the Company had no debt as of year-end 2025.
Fourth Quarter Key Performance Metrics
| ($ in 000s) | Three Months Ended Dec. 31, | Y-o-Y | Twelve Months Ended Dec. 31, | Y-o-Y | |||||||||||
| Key Performance Metrics |
2025 |
2024 |
% Growth |
2025 |
2024 |
% Growth | |||||||||
| Revenue | |||||||||||||||
| Revenue | $ | 46,868 | $ | 45,137 | 4 | % | $ | 194,055 | $ | 154,824 | 25 | % | |||
| Adjusted EBITDA | $ | 4,759 | $ | 1,062 | 348 | % | $ | 15,254 | $ | 3,726 | 309 | % | |||
| Active Subscribers | 322,872 | 277,739 | 16 | % | 322,872 | 277,739 | 16 | % | |||||||
Financial Guidance
For the first quarter of 2026, the Company expects:
- Revenue in the range of $48 million to $49 million.
- Adjusted EBITDA loss of $4 million to $5 million, reflecting strategic front-loaded patient acquisition investment spend as the number of GLP-1 patient sign-ups doubled versus Q4 2025.
- Adjusted EBITDA expected to return to profitability in Q2 as customer acquisition costs decline sequentially and the substantial rise in patient volumes becomes accretive for the balance of 2026.
For the full year 2026, the Company expects:
- Revenue in the range of $220 million to $230 million, representing 13% to 19% year-over-year growth. Annualized run-rate revenue expected to exceed $250 million by Q4 2026, driven by GLP-1 and women’s health momentum.
- Adjusted EBITDA in the range of $12 million to $17 million. Annualized run-rate adjusted EBITDA expected to exceed $25 million by Q4 2026, with substantial second-half accretion as weight management and women’s health investments mature.
Conference Call
LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:
Toll-free dial-in number: 800-343-5172
International dial-in number: 203-518-9856
Conference ID: LIFEMD
A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
[email protected]
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
[email protected]
Tables to Follow
| LIFEMD, INC. | ||||||
| CONSOLIDATED BALANCE SHEETS | ||||||
| December 31, 2025 | December 31, 2024 | |||||
| ASSETS | ||||||
| Current Assets | ||||||
| Cash | $ | 36,786,318 | $ | 32,651,801 | ||
| Accounts receivable | 9,305,277 | 10,455,813 | ||||
| Product deposit | 320,217 | 40,763 | ||||
| Inventory, net | 2,773,576 | 2,797,358 | ||||
| Other current assets | 2,646,077 | 3,003,539 | ||||
| Current assets of discontinued operations | – | 3,420,086 | ||||
| Total Current Assets | 51,831,465 | 52,369,360 | ||||
| Non-current Assets | ||||||
| Equipment, net | 2,444,717 | 1,439,573 | ||||
| Right of use assets, net | 5,267,857 | 6,228,559 | ||||
| Capitalized software, net | 10,604,946 | 9,305,919 | ||||
| Intangible assets, net | 262,334 | 53,336 | ||||
| Non-current assets of discontinued operations | – | 6,699,550 | ||||
| Total Non-current Assets | 18,579,854 | 23,726,937 | ||||
| Total Assets | $ | 70,411,319 | $ | 76,096,297 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||
| Current Liabilities | ||||||
| Accounts payable | $ | 14,149,154 | $ | 10,904,671 | ||
| Accrued expenses | 15,974,016 | 21,756,619 | ||||
| Current operating lease liabilities | 642,422 | 320,082 | ||||
| Current portion of convertible long-term debt | – | 8,444,444 | ||||
| Deferred revenue | 10,807,773 | 17,097,854 | ||||
| Current liabilities of discontinued operations | – | 8,876,498 | ||||
| Total Current Liabilities | 41,573,365 | 67,400,168 | ||||
| Long-term Liabilities | ||||||
| Convertible long-term debt, net | – | 9,885,057 | ||||
| Non-current operating lease liabilities | 5,681,374 | 6,279,004 | ||||
| Non-current liabilities of discontinued operations | – | 86,188 | ||||
| Total Liabilities | 47,254,739 | 83,650,417 | ||||
| Commitments and Contingencies | ||||||
| Stockholders’ Equity (Deficit) | ||||||
| Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of December 31, 2025 and 2024 | 140 | 140 | ||||
| Common Stock, $0.01 par value; 100,000,000 shares authorized, 46,760,016 and 42,293,907 shares issued, 46,656,976 and 42,190,867 outstanding as of December 31, 2025 and 2024, respectively | 467,600 | 422,939 | ||||
| Additional paid-in capital | 251,455,616 | 230,508,339 | ||||
| Accumulated deficit | (228,603,075) | (239,850,931) | ||||
| Treasury stock, 103,040 shares, at cost, as of December 31, 2025 and 2024 | (163,701) | (163,701) | ||||
| Total LifeMD, Inc. Stockholders’ Equity (Deficit) | 23,156,580 | (9,083,214) | ||||
| Non-controlling interest of discontinued operations | – | 1,529,094 | ||||
| Total Stockholders’ Equity (Deficit) | 23,156,580 | (7,554,120) | ||||
| Total Liabilities and Stockholders’ Equity (Deficit) | $ | 70,411,319 | $ | 76,096,297 | ||
| LIFEMD, INC. | ||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||
|
Fourth Quarter Ended December 31, |
Year Ended December 31, |
|||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||
| Telehealth revenue, net | $ | 46,868,484 | $ | 45,137,021 | $ | 194,055,198 | $ | 154,824,075 | ||||||
| Cost of telehealth revenue | 6,025,408 | 8,391,484 | 27,714,808 | 21,440,799 | ||||||||||
| Gross profit | 40,843,076 | 36,745,537 | 166,340,390 | 133,383,276 | ||||||||||
| Expenses | ||||||||||||||
| Selling and marketing expenses | 19,086,443 | 17,819,834 | 86,074,473 | 70,102,961 | ||||||||||
| General and administrative expenses | 15,541,255 | 16,603,620 | 57,937,023 | 57,947,932 | ||||||||||
| Customer service expenses | 2,493,087 | 2,831,985 | 11,579,636 | 10,217,654 | ||||||||||
| Other operating expenses | 3,000,591 | 2,663,872 | 11,073,155 | 8,659,712 | ||||||||||
| Development costs | 1,819,418 | 1,670,906 | 7,345,797 | 6,857,005 | ||||||||||
| Total expenses | 41,940,794 | 41,590,217 | 174,010,084 | 153,785,264 | ||||||||||
| Operating loss from continuing operations | (1,097,718) | (4,844,680) | (7,669,694) | (20,401,988) | ||||||||||
| Other expenses | ||||||||||||||
| Interest expense, net | 24,079 | (610,954) | (1,360,967) | (2,175,405) | ||||||||||
| Loss on debt extinguishment | – | – | (1,155,851) | – | ||||||||||
| Loss from continuing operations before income taxes | (1,073,639) | (5,455,634) | (10,186,512) | (22,577,393) | ||||||||||
| Income tax provision | (13,898) | (598,000) | (45,721) | (598,000) | ||||||||||
| Net loss from continuing operations | (1,087,537) | (6,053,634) | (10,232,233) | (23,175,393) | ||||||||||
| Net income from discontinued operations | 21,030,505 | 1,426,807 | 25,852,024 | 2,315,252 | ||||||||||
| Net income (loss) | 19,942,968 | (4,626,827) | 15,619,791 | (20,860,141) | ||||||||||
| Net (loss) income attributable to noncontrolling interests of discontinued operations | (20,697) | 311,838 | 1,265,685 | 548,875 | ||||||||||
| Net income (loss) attributable to LifeMD, Inc. | 19,963,665 | (4,938,665) | 14,354,106 | (21,409,016) | ||||||||||
| Preferred stock dividends | (776,562) | (776,562) | (3,106,250) | (3,106,250) | ||||||||||
| Net income (loss) attributable to LifeMD, Inc. common stockholders | $ | 19,187,103 | $ | (5,715,227) | $ | 11,247,856 | $ | (24,515,266) | ||||||
| Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders | ||||||||||||||
| Continuing operations | $ | (0.04) | $ | (0.16) | $ | (0.30) | $ | (0.64) | ||||||
| Discontinued operations | 0.45 | 0.03 | 0.54 | 0.04 | ||||||||||
| Basic earnings (loss) per share | $ | 0.41 | $ | (0.14) | $ | 0.25 | $ | (0.60) | ||||||
| Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders | ||||||||||||||
| Continuing operations | $ | (0.04) | $ | (0.16) | $ | (0.30) | $ | (0.64) | ||||||
| Discontinued operations | 0.45 | 0.03 | 0.54 | 0.04 | ||||||||||
| Diluted earnings (loss) per share | $ | 0.41 | $ | (0.14) | $ | 0.25 | $ | (0.60) | ||||||
| Weighted average number of common shares outstanding: | ||||||||||||||
| Basic | 46,773,743 | 42,205,767 | 45,129,617 | 41,196,292 | ||||||||||
| Diluted | 46,773,743 | 42,205,767 | 45,129,617 | 41,196,292 | ||||||||||
| LIFEMD, INC. | |||||||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||
|
Fourth Quarter Ended December 31, |
Year Ended December 31, |
||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||||||
| Net income (loss) | $ | 19,942,968 | $ | (4,626,827) | $ | 15,619,791 | $ | (20,860,141) | |||||
| Less: Net income from discontinued operations | 21,030,505 | 1,426,807 | 25,852,024 | 2,315,252 | |||||||||
| Net loss from continuing operations | (1,087,537) | (6,053,634) | (10,232,233) | (23,175,393) | |||||||||
| Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities: | |||||||||||||
| Amortization of debt discount | – | 100,444 | 234,369 | 401,775 | |||||||||
| Amortization of capitalized software | 1,636,200 | 1,481,039 | 6,348,932 | 5,696,865 | |||||||||
| Amortization of intangibles | 31,918 | 6,666 | 94,002 | 26,667 | |||||||||
| Accretion of consideration payable | – | – | – | 13,644 | |||||||||
| Depreciation of fixed assets | 281,609 | 159,380 | 865,524 | 465,830 | |||||||||
| Write-down of inventory | – | 675,669 | – | 675,669 | |||||||||
| Loss on debt extinguishment | – | – | 1,155,851 | – | |||||||||
| Noncash operating lease expense | 217,495 | 220,622 | 960,702 | 672,983 | |||||||||
| Stock compensation expense | 2,655,143 | 3,104,956 | 10,496,321 | 12,234,797 | |||||||||
| Changes in Assets and Liabilities | |||||||||||||
| Accounts receivable | (363,895) | 661,327 | 1,150,536 | (4,487,546) | |||||||||
| Product deposit | 50,301 | 95,992 | (279,454) | 445,087 | |||||||||
| Inventory | 658,806 | (827,584) | 23,782 | (713,095) | |||||||||
| Other current assets | 915,702 | (121,682) | 357,463 | (2,270,374) | |||||||||
| Operating lease liabilities | (103,449) | (13,780) | (275,290) | (381,189) | |||||||||
| Deferred revenue | (1,340,226) | (933,283) | (6,290,081) | 9,826,219 | |||||||||
| Accounts payable | (651,595) | 1,043,605 | 3,244,483 | 4,176,113 | |||||||||
| Accrued expenses | (4,998,738) | 662,521 | (5,782,603) | 10,755,261 | |||||||||
| Net cash (used in) provided by operating activities of continuing operations | (2,098,266) | 262,258 | 2,072,304 | 14,363,313 | |||||||||
| Net cash (used in) provided by operating activities of discontinued operations | (1,182,257) | 811,043 | 6,207,871 | 3,149,877 | |||||||||
| Net cash (used in) provided by operating activities | (3,280,523) | 1,073,301 | 8,280,175 | 17,513,190 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||||||
| Cash paid for capitalized software costs | (1,763,287) | (1,601,100) | (7,647,959) | (6,738,742) | |||||||||
| Purchase of equipment | (190,704) | (212,287) | (1,870,668) | (1,463,357) | |||||||||
| Net cash used in investing activities of continuing operations | (1,953,991) | (1,813,387) | (9,518,627) | (8,202,099) | |||||||||
| Net cash provided by (used in) investing activities of discontinued operations | 19,023,623 | (907,340) | 16,426,858 | (3,334,219) | |||||||||
| Net cash provided by (used in) investing activities | 17,069,632 | (2,720,727) | 6,908,231 | (11,536,318) | |||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||||||
| Repayment of debt instruments | – | – | (18,719,721) | – | |||||||||
| Sale of common stock under ATM, net | – | – | 8,721,717 | – | |||||||||
| Repayment of notes payable, net of prepayment penalty | – | – | – | (327,597) | |||||||||
| Cash proceeds from exercise of warrants | – | – | 464,950 | – | |||||||||
| Cash proceeds from exercise of options | – | 12,499 | 5,950 | 120,312 | |||||||||
| Preferred stock dividends | (776,562) | (776,562) | (3,106,250) | (3,106,250) | |||||||||
| Net cash used in financing activities of continuing operations | (776,562) | (764,063) | (12,633,354) | (3,313,535) | |||||||||
| Net cash used in financing activities of discontinued operations | (12,000) | (170,840) | (773,658) | (805,138) | |||||||||
| Net cash used in financing activities | (788,562) | (934,903) | (13,407,012) | (4,118,673) | |||||||||
| Net increase (decrease) in cash | 13,000,547 | (2,582,329) | 1,781,394 | 1,858,199 | |||||||||
| Cash at beginning of period | 23,785,771 | 37,587,253 | 35,004,924 | 33,146,725 | |||||||||
| Cash at end of year | 36,786,318 | 35,004,924 | 36,786,318 | 35,004,924 | |||||||||
| Less: Cash of discontinued operations at end of year | – | 2,353,123 | – | 2,353,123 | |||||||||
| Cash of continuing operations at end of year | $ | 36,786,318 | $ | 32,651,801 | $ | 36,786,318 | $ | 32,651,801 | |||||
| Cash paid for interest and taxes | |||||||||||||
| Cash paid during the period for interest | $ | – | $ | 614,993 | $ | 1,461,032 | $ | 2,528,042 | |||||
| Cash paid during the period for taxes | $ | 184,791 | $ | 16,035 | $ | 667,262 | $ | 214,211 | |||||
| Non-cash investing and financing activities: | |||||||||||||
| Cashless exercise of options | $ | – | $ | – | $ | 1,315 | $ | 5,127 | |||||
| Cashless exercise of warrants | $ | – | $ | – | $ | 3,901 | $ | 16,305 | |||||
| Stock issued for debt conversion | $ | – | $ | – | $ | 1,000,000 | $ | – | |||||
| Stock issued for asset acquisition | $ | – | $ | – | $ | 303,000 | $ | – | |||||
| Stock issued for noncontingent consideration payments | $ | – | $ | – | $ | – | $ | 642,000 | |||||
| Operating lease liabilities arising from obtaining right of use assets | $ | – | $ | (102,618) | $ | – | $ | 6,372,148 | |||||
About the Use of Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. We believe that the presentation of this financial measure enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.
Adjusted EBITDA is defined as net income (loss) attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests of discontinued operations, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses, stock-based compensation expense and net income from discontinued operations. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, its most directly comparable GAAP financial measure.
We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA may vary from that of others in our industry. Adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.
|
Reconciliation of Net Income (Loss) Attributable to LifeMD, Inc. Common Stockholders to Adjusted EBITDA |
||||||||||||||
| (in whole numbers, unaudited) | ||||||||||||||
|
Fourth Quarter Ended December 31, |
Year Ended December 31, |
|||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||
| Net income (loss) attributable to LifeMD, Inc. common stockholders | $ | 19,187,103 | $ | (5,715,227) | $ | 11,247,856 | $ | (24,515,266) | ||||||
| Interest (income) expense (excluding amortization of debt discount) | (24,079) | 510,510 | 1,126,598 | 1,773,630 | ||||||||||
| Depreciation, amortization and accretion expense | 1,949,727 | 1,647,085 | 7,308,458 | 6,203,006 | ||||||||||
| Amortization of debt discount | – | 100,444 | 234,369 | 401,775 | ||||||||||
| Loss on debt extinguishment | – | – | 1,155,851 | – | ||||||||||
| Financing transactions expense | 36,716 | 13,125 | 134,415 | 336,497 | ||||||||||
| Litigation costs(a) | 573,894 | 376,030 | 2,273,355 | 1,698,531 | ||||||||||
| Severance costs | 266,863 | – | 369,280 | 1,142,068 | ||||||||||
| Acquisitions expenses | 211,836 | 537,662 | 1,995,042 | 537,662 | ||||||||||
| Insurance acceptance readiness | – | 92,661 | 183,330 | 1,454,298 | ||||||||||
| Sarbanes Oxley readiness | – | 134,891 | – | 521,361 | ||||||||||
| Taxes | 176,925 | 598,000 | 208,748 | 598,000 | ||||||||||
| Preferred stock dividends | 776,562 | 776,562 | 3,106,250 | 3,106,250 | ||||||||||
| Stock compensation expense | 2,655,143 | 3,104,956 | 10,496,321 | 12,234,797 | ||||||||||
| Net income from discontinued operations | (21,030,505) | (1,426,807) | (25,852,024) | (2,315,252) | ||||||||||
| Net (loss) income attributable to noncontrolling interests of discontinued operations | (20,697) | 311,838 | 1,265,685 | 548,875 | ||||||||||
| Adjusted EBITDA | $ | 4,759,487 | $ | 1,061,729 | $ | 15,253,533 | $ | 3,726,231 | ||||||
| (a)For the fourth quarter and year ended December 31, 2025 and 2024, the Company included costs related to: (1) a class action complaint captionedJohnston v. LifeMD, Inc., et al., against the Company and certain executive officers alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder by all defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Securities Exchange Act of 1934, as amended, by the individual officer defendants for violating their duty to disseminate accurate and truthful information, (2) a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (theMarden v. LifeMD, Inc.case), both disclosed in the Company’s Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and (3) a heavily negotiated executive separation agreement. | ||||||||||||||
